BRUKER CORP (BRKR) Stock Fundamental Analysis
NASDAQ:BRKR - Nasdaq - US1167941087 - Common Stock - Currency: USD
Overall BRKR gets a fundamental rating of 4 out of 10. We evaluated BRKR against 55 industry peers in the Life Sciences Tools & Services industry. While BRKR is still in line with the averages on profitability rating, there are concerns on its financial health. BRKR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
BRKR had positive earnings in the past year.
In the past year BRKR had a positive cash flow from operations.
Each year in the past 5 years BRKR has been profitable.
BRKR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of 1.95%, BRKR is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Looking at the Return On Equity, with a value of 6.35%, BRKR is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
BRKR's Return On Invested Capital of 5.74% is fine compared to the rest of the industry. BRKR outperforms 69.09% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BRKR is below the industry average of 13.27%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.95% | ||
| ROE | 6.35% | ||
| ROIC | 5.74% |
ROA(3y)6.74%
ROA(5y)6.6%
ROE(3y)21.33%
ROE(5y)21.26%
ROIC(3y)9.3%
ROIC(5y)9.28%
1.3 Margins
BRKR has a Profit Margin of 3.36%. This is in the better half of the industry: BRKR outperforms 70.91% of its industry peers.
BRKR's Profit Margin has declined in the last couple of years.
BRKR's Operating Margin of 11.50% is fine compared to the rest of the industry. BRKR outperforms 69.09% of its industry peers.
In the last couple of years the Operating Margin of BRKR has declined.
BRKR has a Gross Margin (49.34%) which is comparable to the rest of the industry.
BRKR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.5% | ||
| PM (TTM) | 3.36% | ||
| GM | 49.34% |
OM growth 3Y-13.3%
OM growth 5Y-4.84%
PM growth 3Y-33.57%
PM growth 5Y-18.8%
GM growth 3Y-0.46%
GM growth 5Y0.54%
2. Health
2.1 Basic Checks
BRKR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BRKR has been increased compared to 1 year ago.
BRKR has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BRKR has a worse debt to assets ratio.
2.2 Solvency
BRKR has an Altman-Z score of 2.41. This is not the best score and indicates that BRKR is in the grey zone with still only limited risk for bankruptcy at the moment.
BRKR's Altman-Z score of 2.41 is fine compared to the rest of the industry. BRKR outperforms 61.82% of its industry peers.
The Debt to FCF ratio of BRKR is 15.40, which is on the high side as it means it would take BRKR, 15.40 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BRKR (15.40) is comparable to the rest of the industry.
BRKR has a Debt/Equity ratio of 1.16. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.16, BRKR is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.16 | ||
| Debt/FCF | 15.4 | ||
| Altman-Z | 2.41 |
ROIC/WACC0.6
WACC9.63%
2.3 Liquidity
BRKR has a Current Ratio of 1.60. This is a normal value and indicates that BRKR is financially healthy and should not expect problems in meeting its short term obligations.
BRKR has a worse Current ratio (1.60) than 70.91% of its industry peers.
BRKR has a Quick Ratio of 1.60. This is a bad value and indicates that BRKR is not financially healthy enough and could expect problems in meeting its short term obligations.
BRKR has a worse Quick ratio (0.75) than 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
BRKR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.56%.
BRKR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.95% yearly.
Looking at the last year, BRKR shows a quite strong growth in Revenue. The Revenue has grown by 13.56% in the last year.
The Revenue has been growing by 10.19% on average over the past years. This is quite good.
EPS 1Y (TTM)-8.56%
EPS 3Y4.7%
EPS 5Y8.95%
EPS Q2Q%-11.32%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y11.66%
Revenue growth 5Y10.19%
Sales Q2Q%11.04%
3.2 Future
Based on estimates for the next years, BRKR will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.14% on average per year.
Based on estimates for the next years, BRKR will show a small growth in Revenue. The Revenue will grow by 5.38% on average per year.
EPS Next Y10.74%
EPS Next 2Y13.11%
EPS Next 3Y13.62%
EPS Next 5Y13.14%
Revenue Next Year4.5%
Revenue Next 2Y4.63%
Revenue Next 3Y5.07%
Revenue Next 5Y5.38%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BRKR is valuated correctly with a Price/Earnings ratio of 16.49.
BRKR's Price/Earnings ratio is rather cheap when compared to the industry. BRKR is cheaper than 87.27% of the companies in the same industry.
BRKR's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.95.
The Price/Forward Earnings ratio is 12.56, which indicates a correct valuation of BRKR.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BRKR indicates a rather cheap valuation: BRKR is cheaper than 90.91% of the companies listed in the same industry.
BRKR's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.99.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.49 | ||
| Fwd PE | 12.56 |
4.2 Price Multiples
BRKR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BRKR is cheaper than 85.45% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BRKR is valued a bit cheaper than 63.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.16 | ||
| EV/EBITDA | 13.63 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BRKR's earnings are expected to grow with 13.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.53
PEG (5Y)1.84
EPS Next 2Y13.11%
EPS Next 3Y13.62%
5. Dividend
5.1 Amount
BRKR has a yearly dividend return of 0.50%, which is pretty low.
The stock price of BRKR dropped by -22.58% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
BRKR's Dividend Yield is rather good when compared to the industry average which is at 0.51. BRKR pays more dividend than 90.91% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, BRKR's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.5% |
5.2 History
The dividend of BRKR has a limited annual growth rate of 4.81%.
BRKR has paid a dividend for at least 10 years, which is a reliable track record.
As BRKR did not decrease their dividend in the past 5 years, we can say the dividend looks stable.
Dividend Growth(5Y)4.81%
Div Incr Years0
Div Non Decr Years7
5.3 Sustainability
BRKR pays out 26.70% of its income as dividend. This is a sustainable payout ratio.
BRKR's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP26.7%
EPS Next 2Y13.11%
EPS Next 3Y13.62%
38.74
-1.52 (-3.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners82.93%
Inst Owner Change0.01%
Ins Owners26.92%
Ins Owner Change0.32%
Market Cap5.87B
Analysts77.27
Price Target59.61 (53.87%)
Short Float %7.19%
Short Ratio2.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.5% |
Yearly Dividend0.2
Dividend Growth(5Y)4.81%
DP26.7%
Div Incr Years0
Div Non Decr Years7
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.13%
Min EPS beat(2)-0.9%
Max EPS beat(2)1.16%
EPS beat(4)2
Avg EPS beat(4)2.43%
Min EPS beat(4)-2.58%
Max EPS beat(4)12.06%
EPS beat(8)6
Avg EPS beat(8)6.88%
EPS beat(12)9
Avg EPS beat(12)7.2%
EPS beat(16)12
Avg EPS beat(16)10.84%
Revenue beat(2)0
Avg Revenue beat(2)-1%
Min Revenue beat(2)-1.39%
Max Revenue beat(2)-0.62%
Revenue beat(4)0
Avg Revenue beat(4)-1.63%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)-0.62%
Revenue beat(8)4
Avg Revenue beat(8)0.92%
Revenue beat(12)7
Avg Revenue beat(12)1%
Revenue beat(16)11
Avg Revenue beat(16)1.66%
PT rev (1m)-11.81%
PT rev (3m)-18.95%
EPS NQ rev (1m)1.58%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)-1.68%
EPS NY rev (3m)-2.24%
Revenue NQ rev (1m)0.75%
Revenue NQ rev (3m)-5.69%
Revenue NY rev (1m)0.51%
Revenue NY rev (3m)-1.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.49 | ||
| Fwd PE | 12.56 | ||
| P/S | 1.74 | ||
| P/FCF | 43.16 | ||
| P/OCF | 23.36 | ||
| P/B | 3.3 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.63 |
EPS(TTM)2.35
EY6.07%
EPS(NY)3.08
Fwd EY7.96%
FCF(TTM)0.9
FCFY2.32%
OCF(TTM)1.66
OCFY4.28%
SpS22.22
BVpS11.76
TBVpS-4.21
PEG (NY)1.53
PEG (5Y)1.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.95% | ||
| ROE | 6.35% | ||
| ROCE | 8.55% | ||
| ROIC | 5.74% | ||
| ROICexc | 5.98% | ||
| ROICexgc | 13.51% | ||
| OM | 11.5% | ||
| PM (TTM) | 3.36% | ||
| GM | 49.34% | ||
| FCFM | 4.04% |
ROA(3y)6.74%
ROA(5y)6.6%
ROE(3y)21.33%
ROE(5y)21.26%
ROIC(3y)9.3%
ROIC(5y)9.28%
ROICexc(3y)11.26%
ROICexc(5y)12.82%
ROICexgc(3y)18.89%
ROICexgc(5y)20.78%
ROCE(3y)13.86%
ROCE(5y)13.83%
ROICexcg growth 3Y-22.35%
ROICexcg growth 5Y-9.61%
ROICexc growth 3Y-31.42%
ROICexc growth 5Y-15.9%
OM growth 3Y-13.3%
OM growth 5Y-4.84%
PM growth 3Y-33.57%
PM growth 5Y-18.8%
GM growth 3Y-0.46%
GM growth 5Y0.54%
F-Score3
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.16 | ||
| Debt/FCF | 15.4 | ||
| Debt/EBITDA | 3.61 | ||
| Cap/Depr | 62.73% | ||
| Cap/Sales | 3.43% | ||
| Interest Coverage | 7.09 | ||
| Cash Conversion | 44.03% | ||
| Profit Quality | 120.25% | ||
| Current Ratio | 1.6 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | 2.41 |
F-Score3
WACC9.63%
ROIC/WACC0.6
Cap/Depr(3y)100.42%
Cap/Depr(5y)105.08%
Cap/Sales(3y)4.05%
Cap/Sales(5y)4.17%
Profit Quality(3y)75.38%
Profit Quality(5y)88.75%
High Growth Momentum
Growth
EPS 1Y (TTM)-8.56%
EPS 3Y4.7%
EPS 5Y8.95%
EPS Q2Q%-11.32%
EPS Next Y10.74%
EPS Next 2Y13.11%
EPS Next 3Y13.62%
EPS Next 5Y13.14%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y11.66%
Revenue growth 5Y10.19%
Sales Q2Q%11.04%
Revenue Next Year4.5%
Revenue Next 2Y4.63%
Revenue Next 3Y5.07%
Revenue Next 5Y5.38%
EBIT growth 1Y-20.48%
EBIT growth 3Y-3.19%
EBIT growth 5Y4.86%
EBIT Next Year36.69%
EBIT Next 3Y19.2%
EBIT Next 5Y17.94%
FCF growth 1Y-44.08%
FCF growth 3Y-10.61%
FCF growth 5Y-0.63%
OCF growth 1Y-28.22%
OCF growth 3Y-3.81%
OCF growth 5Y3.32%